Truseltiq (Infigratinib)
Truseltiq™ (infigratinib), a kinase inhibitor, is indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as determined by a test approved by the US Food and Drug Administration (FDA).1 Cholangiocarcinomas (CCAs) are cancers that develop in…